These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4941 related articles for article (PubMed ID: 6216086)

  • 21. Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice.
    Maestroni GJ; Covacci V; Conti A
    Cancer Res; 1994 May; 54(9):2429-32. PubMed ID: 8162592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the tumor-host relationship. II. Serum resistant factor(s) produced by tumor transplantation.
    Tanino T
    Jpn J Exp Med; 1968 Oct; 38(5):383-92. PubMed ID: 5305973
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro and in vivo activities of long-term cultured veto suppressor clones.
    Yanagie H; Takeda Y; Maki T
    Transplant Proc; 1993 Feb; 25(1 Pt 1):350-1. PubMed ID: 8438330
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumor growth inhibitory and natural suppressor activities of murine bone marrow cells: a comparative study.
    Seledtsov VI; Taraban VY; Seledtsova GV; Samarin DM; Avdeev IV; Senyukov VV; Kozlov VA
    Cell Immunol; 1997 Nov; 182(1):12-9. PubMed ID: 9427805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Change in the cross reactivity of MIF producers during the course of the immune response in the H-2 system].
    Suslov AP; Gering S; Kharkevich DD; Blandova ZK
    Biull Eksp Biol Med; 1980 Apr; 89(4):437-9. PubMed ID: 6992883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Induction of T-cells--producers of macrophage migration inhibitory factors by mutant H-2 antigens in vivo].
    Kharkevich DD; Suslov AP; Blandova ZK
    Biull Eksp Biol Med; 1984 Apr; 97(4):443-5. PubMed ID: 6372888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune reactivity of spleen cells in advanced stages of tumor growth.
    Oisgold-Dagá S; Jasnis MA; Klein S; de Bonaparte YP
    Biomed Pharmacother; 1982; 36(6-7):319-23. PubMed ID: 6763881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis.
    Shimizu T; Abe R; Nakamura H; Ohkawara A; Suzuki M; Nishihira J
    Biochem Biophys Res Commun; 1999 Nov; 264(3):751-8. PubMed ID: 10544003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Genetic control of production of a lymphokine inhibiting macrophage migration in mice].
    Petrov RV; Koval'chuk LV; Sokolova EV; Burtseva LV
    Genetika; 1980; 16(10):1825-33. PubMed ID: 7007159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrasting effects of activated and nonactivated macrophages and macrophages from tumor-bearing mice on tumor growth in vivo.
    Gabizon A; Leibovich SJ; Goldman R
    J Natl Cancer Inst; 1980 Nov; 65(5):913-20. PubMed ID: 6933261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetic studies of macrophages. VI. The effect of the presence of a solid tumor.
    Gillette RW; Boone CW
    J Reticuloendothel Soc; 1974 Feb; 15(2):126-31. PubMed ID: 4815212
    [No Abstract]   [Full Text] [Related]  

  • 32. An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis.
    Ogawa H; Nishihira J; Sato Y; Kondo M; Takahashi N; Oshima T; Todo S
    Cytokine; 2000 Apr; 12(4):309-14. PubMed ID: 10805210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches.
    Sapoznikov A; Pewzner-Jung Y; Kalchenko V; Krauthgamer R; Shachar I; Jung S
    Nat Immunol; 2008 Apr; 9(4):388-95. PubMed ID: 18311142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Murine splenocyte migration inhibition assay I. Detection of differential responses to murine leukemia P388 and its adriamycin-resistant subline P388/ADR.
    Nori M; Gothoskar BP
    Neoplasma; 1983; 30(3):287-93. PubMed ID: 6223231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage production by the bone marrow of tumor-bearing mice.
    Baum M; Fisher B
    Cancer Res; 1972 Dec; 32(12):2813-7. PubMed ID: 4644210
    [No Abstract]   [Full Text] [Related]  

  • 36. Active immunization against macrophage migration inhibitory factor using a novel DNA vaccine prevents ovariectomy-induced bone loss in mice.
    Onodera S; Oshima S; Nishihira J; Yasuda K; Tohyama H; Irie K; Koyama Y
    Vaccine; 2008 Feb; 26(6):829-36. PubMed ID: 18178295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Yang S; Darrow TL; Vervaert CE; Seigler HF
    Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negative and positive immunobiological responses in mice pretreated with Bacillus Calmette-Guérin cell wall.
    Mizushima Y; Wepsic HT; Yamamura Y; DeSilva MA; Janns G; Larson CH
    Cancer Res; 1984 Jan; 44(1):20-4. PubMed ID: 6228292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardiac allograft rejection in the absence of macrophage migration inhibitory factor.
    Demir Y; Chen Y; Metz C; Renz H; Heeger PS
    Transplantation; 2003 Jul; 76(1):244-7. PubMed ID: 12865817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 248.